Hualan Biological Engineering: Net profit fell 26.6% as vaccine sales dropped, but blood products revenue grew 10.9%

About this update from Hualan Biological Engineering Inc. Class A

Revenue and net profit declined year-over-year due to vaccine market contraction and price competition, while blood products showed stable growth. R&D investment increased, and a major vaccine price cut is expected to impact short-term revenue but may drive future market expansion.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Hualan Biological Engineering Inc. Class A